PLATELET‐ACTIVATING FACTOR (PAF) IN EXPERIMENTAL AND CLINICAL SEPSIS

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Shock

• Publication date

  1997-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00024382-199706000-00001PMID 9185238
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical and experimental studies on the role of platelet-activating factor (PAF) in the pathogenesis of septic DIC

  2004cited by this paper
• ATTENUATION OF ENDOTOXIN‐INDUCED PATHOPHYSIOLOGY BY A NEW POTENT PAF RECEPTOR ANTAGONIST

  1996cited by this paper
• ABT‐299, A NOVEL PAF ANTAGONIST, ATTENUATES MULTIPLE EFFECTS OF ENDOTOXEMIA IN CONSCIOUS RATS

  1996cited by this paper
• TREATMENT WITH THE PLATELET-ACTIVATING FACTOR ANTAGONIST TCV-309 IN PATIENTS WITH SEVERE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: A PROSPECTIVE, MULTI-CENTER, DOUBLEBLIND, RANDOMIZED PHASE II TRIAL;

  1996cited by this paper
• Mechanisms of pulmonary vasoconstriction and bronchoconstriction produced by PAF in the guinea‐pig: role of platelets and cyclo‐oxygenase metabolites

  1995cited by this paper
• IL-1 beta and IL-6 stimulate the production of platelet-activating factor (PAF) by cultured rabbit synovial cells.

  1995cited by this paper
• Platelet activating factor modulates microvascular permeability through nitric oxide synthesis.

  1995cited by this paper
• Interleukin-1-induced leukocyte extravasation across rat mesenteric microvessels is mediated by platelet-activating factor.

  1995cited by this paper
• Up-regulation of inducible cyclooxygenase gene expression by platelet-activating factor in activated rat alveolar macrophages.

  1995cited by this paper
• Lipopolysaccharide binding protein and CD14 modulate the synthesis of platelet-activating factor by human monocytes and mesangial and endothelial cells stimulated with lipopolysaccharide.

  1995cited by this paper
• The effect of SRI 63-675, a competitive platelet-activating factor receptor-antagonist, in the generalized Shwartzman reaction.

  1994cited by this paper
• Platelet and plasma platelet-activating factor in sepsis and myocardial infarction.

  1994cited by this paper
• Platelet-activating factor antagonists suppress the generation of tumor necrosis factor-alpha and superoxide induced by lipopolysaccharide or phorbol ester in rat liver macrophages.

  1994cited by this paper
• Platelet-activating factor and phospholipase A2 in patients with septic shock and trauma

  1994cited by this paper
• Effect of CL 184,005, a platelet-activating factor antagonist in a murine model of Staphylococcus aureus-induced gram-positive sepsis.

  1994cited by this paper
• Sepsis and its complications: clinical definitions and therapeutic prospects.

  1994cited by this paper
• Platelet-activating factor and endotoxin induce tumour necrosis factor gene expression in rat intestine and liver.

  1994cited by this paper
• Delayed treatment with platelet activating factor receptor antagonist web 2086 attenuates pulmonary dysfunction in porcine endotoxin shock.

  1994cited by this paper
• Platelet Shape Change in Whole Blood: Differential Effects of Endotoxin

  1994cited by this paper
• Effect of the platelet activating factor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride on endotoxin-induced hypotension and hematological parameters in rats.

  1994cited by this paper
• Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.

  1994cited by this paper
• A new method of purification and sensitive bioassay of platelet-activating factor (PAF) in human whole blood.

  1994cited by this paper
• Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs.

  1994cited by this paper
• THE ROLE OF PLATELET‐ACTIVATING FACTOR IN ALTERATIONS OF SYSTEM A AMINO ACID TRANSPORT IN RAT SOLEUS AND EXTENSOR DIGITORUM LONGUS MUSCLES DURING ENDOTOXIC SHOCK

  1994cited by this paper
• The production of experimental cholecystitis by endotoxin.

  1994cited by this paper
• The role of endogenous nitric oxide and platelet-activating factor in hypoxia-induced intestinal injury in rats.

  1994cited by this paper
• In pigs, inhaled nitric oxide (NO) counterbalances PAF-induced pulmonary hypertension.

  1994cited by this paper
• Platelet activating factor impairs pressor responses to noradrenaline in the anaesthetized rat but does not mediate endotoxin-induced hyporeactivity.

  1994cited by this paper
• Physiologic support of the septic patient.

  1994cited by this paper
• BENEFICIAL EFFECTS OF A NOVEL PLATELET‐ACTIVATING FACTOR RECEPTOR ANTAGONIST, ST 899, ON ENDOTOXIN‐INDUCED SHOCK IN MICE

  1994cited by this paper
• Platelet activating factor-antagonist improves survival in experimental staphylococcal septicemia.

  1994cited by this paper
• The metabolic effects of platelet-activating factor antagonism in endotoxemic man.

  1994cited by this paper
• Essential fatty acid-deficient diet modifies PAF levels in stomach and duodenum of endotoxin-treated rats.

  1994cited by this paper
• Platelet‐activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double‐blind, placebo‐controlled, multicenter clinical trial

  1994cited by this paper
• Involvement of a serine protease in the synthesis of platelet-activating factor by endothelial cells stimulated by tumor necrosis factor-alpha or interleukin-1 alpha.

  1994cited by this paper
• Modulation by nitric oxide of platelet‐activating factor‐induced albumin extravasation in the conscious rat

  1993cited by this paper
• Endogenous Nitric Oxide Protects against Platelet-Activating Factor-Induced Bowel Injury in the Rat

  1993cited by this paper
• Vasodilator and constrictor actions of platelet-activating factor in the isolated microperfused afferent arteriole of the rabbit kidney. Role of endothelium-derived relaxing factor/nitric oxide and cyclooxygenase products.

  1993cited by this paper
• Systemic and regional hemodynamic changes during endotoxin or platelet activating factor (PAF)-induced shock in rats.

  1993cited by this paper
• Involvement of platelet-activating factor (PAF) in endotoxin- or ischaemia-induced intestinal hyperpermeability in the rat.

  1993cited by this paper
• Administration of a receptor antagonist for platelet-activating factor during equine endotoxaemia.

  1993cited by this paper
• Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide.

  1993cited by this paper
• Hemodynamic and regional blood flow responses of neonatal and adult dogs to endotoxin challenge.

  1993cited by this paper
• Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.

  1993cited by this paper
• Effect of platelet-activating factor on basal and insulin-mediated system A amino acid transport in rat soleus muscle.

  1993cited by this paper
• ARDS-like lung injury produced by endotoxin in platelet-activating factor-primed rats.

  1993cited by this paper
• Effect of the platelet‐activating factor antagonist, TCV‐309, and the cyclo‐oxygenase inhibitor, ibuprofen, on the haemodynamic changes in canine experimental endotoxic shock

  1993cited by this paper
• Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.

  1992cited by this paper
• Role of complement in endotoxin/platelet-activating factor-induced lung injury.

  1992cited by this paper
• Time course of various inflammatory mediators during recurrent endotoxemia.

  1992cited by this paper
• Platelet-activating factor antagonists in experimental shock.

  1992cited by this paper
• Platelet-activating factor augments tumor necrosis factor and procoagulant activity.

  1992cited by this paper
• Effect of platelet-activating factor antagonist and leukotriene antagonist on endotoxin shock in the rat: role of the leukocyte.

  1992cited by this paper
• Platelet activating factor mediates interleukin-2-induced lung injury in the rat.

  1992cited by this paper
• Relationship between interleukin-1 beta and platelet-activating factor in the pathogenesis of acute immune complex alveolitis in the rat.

  1992cited by this paper
• Platelet activating factor enhancement of lipopolysaccharide‐induced tissue factor activity in monocytes: requirement of platelets and granulocytes

  1992cited by this paper
• Platelet-activating factor type activity in plasma from patients with septicemia and other diseases

  1991cited by this paper
• Platelet-activating factor in cardiovascular stress situations

  1991cited by this paper
• Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. Effects on microvascular permeability, hypotension and nephrosis.

  1991cited by this paper
• Platelet activating factor is one of the mediators involved in endotoxic shock in pigs.

  1991cited by this paper
• Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.

  1991cited by this paper
• Effect of a platelet activating factor antagonist and antithrombin III on septicemia and endotoxemia in rats.

  1991cited by this paper
• The interrelation between TNF, IL-6, and PAF secretion induced by LPS in an in vivo and in vitro murine model.

  1991cited by this paper
• Dimethyl sulfoxide antagonizes hypotensive, metabolic, and pathologic responses induced by endotoxin.

  1991cited by this paper
• A PAF receptor antagonist, BN 52021, attenuates thromboxane release and improves survival in lethal canine endotoxemia.

  1991cited by this paper
• Platelet-activating factor primes endotoxin-stimulated macrophage procoagulant activity.

  1991cited by this paper
• Primed neutrophils injure rat lung through a platelet-activating factor-dependent mechanism.

  1991cited by this paper
• Involvement of platelet-activating factor in the hypotensive response to zymosan in rats.

  1991cited by this paper
• Effect of platelet-activating factor on tumor necrosis factor-induced superoxide generation from human neutrophils. Possible involvement of G proteins

  1991cited by this paper
• Biological response of guinea pig peritoneal macrophages to platelet-activating factor

  1991cited by this paper
• Priming by platelet-activating factor of endotoxin-induced lung injury and cardiovascular shock.

  1991cited by this paper
• Platelet-activating factor stimulates expression of IL-1 beta mRNA in THP-1 cells

  1991cited by this paper
• Platelet-activating factor (PAF-acether) enhances the concomitant production of tumour necrosis factor-alpha and interleukin-1 by subsets of human monocytes.

  1991cited by this paper
• Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF alpha) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist.

  1990cited by this paper
• Effects of in vivo 'priming' on endotoxin-induced hypotension and tissue injury. The role of PAF and tumor necrosis factor.

  1990cited by this paper
• Generation of platelet activating factor (PAF) by a human lung epithelial cell line.

  1990cited by this paper
• Comparative hemodynamics and cardiovascular effects of endotoxin and platelet-activating factor in rat.

  1990cited by this paper
• Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies.

  1990cited by this paper
• Contribution of platelet activating factor to hemodynamic and sympathetic responses to bacterial endotoxin in conscious rats.

  1990cited by this paper
• Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus.

  1990cited by this paper
• A triazolodiazepine platelet activating factor receptor antagonist (WEB 2086) reduces pulmonary dysfunction during endotoxin shock in swine.

  1990cited by this paper
• Protective effect of BN 50739, a new platelet-activating factor antagonist, in endotoxin-treated rabbits.

  1990cited by this paper
• Platelet activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia.

  1990cited by this paper
• Effects of platelet-activating factor on peripheral blood monocytes: induction and priming for TNF secretion.

  1990cited by this paper
• Effect of long-term treatment with platelet-activating factor on IL-1 and IL-2 production by rat spleen cells.

  1990cited by this paper
• Effect of platelet-activating factor on monocyte activation and production of tumor necrosis factor.

  1989cited by this paper
• Role of platelet activating factor in endotoxemic acute renal failure in the male rat.

  1989cited by this paper
• RP 55778, a PAF receptor antagonist, prevents and reverses LPS-induced hemoconcentration and TNF release.

  1989cited by this paper
• Occupancy of platelet receptors for platelet-activating factor in patients with septicemia.

  1989cited by this paper
• PAF-acether and endotoxin display similar effects on rat mesenteric microvessels: inhibition by specific antagonists.

  1988cited by this paper
• Platelet-activating factor-induced increases in glucose kinetics.

  1988cited by this paper
• Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor

  1987cited by this paper
• Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures.

  1987cited by this paper
• Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock.

  1987cited by this paper
• Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats.

  1987cited by this paper
• Perspectives in platelet-activating factor research.

  1987cited by this paper
• Biological properties of the antagonist SRI 63-441 in the PAF and endotoxin models of hypotension in the rat and dog.

  1987cited by this paper
• Intravascular release of platelet activating factor in children with sepsis.

  1987cited by this paper
• Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Effects of three platelet-activating factor antagonists.

  1987cited by this paper
• Effects of L-652,731, a platelet-activating factor (PAF) receptor antagonist, on PAF- and complement-induced pulmonary hypertension in sheep.

  1987cited by this paper

• Plasmalogens as biomarkers and therapeutic targets

  2025cites this paper
• Humoral Mediators in Sepsis

  2019cites this paper
• Inflammation, not Cholesterol, Is a Cause of Chronic Disease

  2018cites this paper
• Recent advances in the pathophysiology and molecular basis of sepsis‐associated organ dysfunction: Novel therapeutic implications and challenges

  2017cites this paper
• Signalling mechanisms in PAF-induced intestinal failure

  2017cites this paper
• Platelet-activating factor and oxidized phosphatidylcholines do not suppress endotoxin-induced pro-inflammatory signaling among human myeloid and endothelial cells

  2017cites this paper
• Platelet-activating Factor Mediates Endotoxin Tolerance by Regulating Indoleamine 2,3-Dioxygenase-dependent Expression of the Suppressor of Cytokine Signaling 3*

  2017cites this paper
• Lipopolysaccharide Cross-Tolerance Delays Platelet-Activating Factor-Induced Sudden Death in Swiss Albino Mice: Involvement of Cyclooxygenase in Cross-Tolerance

  2016cites this paper
• Badania aktywności przeciwbólowej i przeciwzapalnej wybranych acylowanych pochodnych hydroksyiminowych kwasu oleanolowego

  2015cites this paper
• Platelets in the immune response: Revisiting platelet-activating factor in anaphylaxis.

  2015cites this paper
• The poly-γ-d-glutamic acid capsule surrogate of the Bacillus anthracis capsule induces nitric oxide production via the platelet activating factor receptor signaling pathway.

  2015cites this paper
• O eixo LTB4/MYD88 na inflamação estéril e na sepse em modelos experimentais de diabetes.

  2014cites this paper
• Platelet-activating Factor Contributes to Bacillus anthracis Lethal Toxin-associated Damage*

  2014cites this paper
• Pseudomonas aeruginosa toxin ExoU induces a PAF-dependent impairment of alveolar fibrin turnover secondary to enhanced activation of coagulation and increased expression of plasminogen activator inhibitor-1 in the course of mice pneumosepsis

  2011cites this paper
• Platelet-Activating Factor in Brain: Its Metabolism, Roles, and Involvement in Neurological Disorders

  2011cites this paper
• The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses.

  2010cites this paper
• The development of anti-inflammatory drugs for infectious diseases.

  2010cites this paper
• A systematic review of serologic tests in the diagnosis of necrotizing enterocolitis.

  2009cites this paper
• The Novel Role of Platelet-Activating Factor in Protecting Mice against Lipopolysaccharide-Induced Endotoxic Shock

  2009cites this paper
• Involvement of endogenous leukotriene B4 and platelet‐activating factor in polymorphonuclear leucocyte recruitment to dermal inflammatory sites in rats

  2008cites this paper
• Investigation of lipoteichoic acid structure and function to establish its role in Gram-positive bacterial infections

  2008cites this paper
• UvA-DARE ( Digital Academic Repository ) Pneumomia : an investigation of host defence mechanisms

  2007cites this paper
• Immunomodulation by n-3- versus n-6-rich lipid emulsions in murine acute lung injury—Role of platelet-activating factor receptor

  2007cites this paper
• Cytokines and Sleep: Neuro-Immune Interactions and Regulations

  2007cites this paper
• Platelet-Activating Factor-Acetylhydrolase Can Monodeacylate and Inactivate Lipoteichoic Acid

  2006cites this paper
• Neutrophil Migration in Polymicrobial Sepsis Receptors Accounts for the Impairment of Signaling via Platelet-Activating Factor

  2006cites this paper
• Signaling via Platelet-Activating Factor Receptors Accounts for the Impairment of Neutrophil Migration in Polymicrobial Sepsis1

  2006cites this paper
• Platelet activating factor and its metabolite promote sleep in rabbits.

  2006cites this paper
• Regulating inflammation through the anti-inflammatory enzyme platelet-activating factor-acetylhydrolase.

  2005cites this paper
• Toll-like Receptor 4 Signaling Regulates Cytosolic Phospholipase A2 Activation and Lipid Generation in Lipopolysaccharide-stimulated Macrophages*

  2005cites this paper
• Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial*

  2004cites this paper
• Sepsis and neurology.

  2003cites this paper
• Platelet-Activating Factor Synthesis by Neutrophils, Monocytes, and Endothelial Cells is Modulated by Nitric Oxide Production

  2003cites this paper
• Evaluation of Pgg-Glucan, a Novel Immunomodulator, in in Vitro and Ex Vivo Models of Equine Endotoxemia

  2003cites this paper
• Endotoxins Stimulate Neutrophil Adhesion Followed by Synthesis and Release of Platelet-activating Factor in Microparticles*

  2003cites this paper
• A new model for inflammation-induced preterm birth: the role of platelet-activating factor and Toll-like receptor-4.

  2003cites this paper
• Cytokines and chemokines in serum and urine as early predictors to identify septic patients on intensive care unit.

  2003cites this paper
• Invasion and Killing of Human Endothelial Cells by Viridans Group Streptococci

  2003cites this paper
• Immunological, hematological, and serum biochemical effects of high level dietary fish oil and vitamin E supplementation in the dog

  2003cites this paper
• Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial.

  2003cites this paper
• The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis

  2002cites this paper
• Intracellular Loci Involved in Body Formation In Vivo : Innate Immunity Lipopolysaccharide-Induced Leukocyte Lipid and

  2002cites this paper
• Total parenteral nutrition.

  2002cites this paper
• Bioactive Oxidized Lipids in the Plasma of Cardiac Surgical Intensive Care Patients

  2002cites this paper
• Management of the acute respiratory distress syndrome.

  2002cites this paper
• Lipopolysaccharide-Induced Leukocyte Lipid Body Formation In Vivo: Innate Immunity Elicited Intracellular Loci Involved in Eicosanoid Metabolism1

  2002cites this paper
• Platelet-activating factor does not mediate circulatory failure induced by 35-GHz microwave heating.

  2002cites this paper
• Eicosanoid Metabolism Elicited Intracellular Loci Involved in Body Formation In Vivo: Innate Immunity Lipopolysaccharide-Induced Leukocyte Lipid

  2002cites this paper
• Platelet-activating factor induces lung inflammation and leak in rats: hydrogen peroxide production along neutrophil-lung endothelial cell interfaces.

  2002cites this paper
• Distinct pathways of lipopolysaccharide priming of human neutrophil respiratory burst: Role of lipid mediator synthesis and sensitivity to interleukin-10

  2002cites this paper
• Sepsis: state of the art.

  2001cites this paper
• A review of the adrenal cortex and severe inflammation: quest of the "eucorticoid" state.

  2001cites this paper
• Evolving Concepts in Sepsis and Septic Shock

  2001cites this paper
• Impact of Genomic Variations on Inflammatory Processes and Sepsis

  2001cites this paper
• Risk and Prognosis of Sepsis Current Methods on the Assessment of the Immunological Status

  2001cites this paper
• Cardiac functional and structural alterations induced by endotoxin in rats: Importance of platelet-activating factor

  2001cites this paper
• Neutrophil migration mechanisms, with an emphasis on the pulmonary vasculature.

  2000cites this paper
• PAF, a putative mediator of oral inflammation.

  2000cites this paper
• Fish oil‐supplemented parenteral diets normalize splanchnic blood flow and improve killing of translocated bacteria in a low‐dose endotoxin rat model

  2000cites this paper
• Immunopathogenesis of Severe Sepsis

  2000cites this paper
• Phase II multicenter clinical study of the platelet‐activating factor receptor antagonist BB‐882 in the treatment of sepsis

  2000cites this paper
• Immunomodulation of Cell-Mediated Responses: Is It Feasible?

  2000cites this paper
• Platelet-Activating Factor

  2000cites this paper
• Lipid mediators in the pathophysiology of critical illness

  2000influential citation
• Neutrophil migration during endotoxemia

  1999cites this paper
• Echocardiographic and survival studies in mice undergoing endotoxic shock: effects of genetic ablation of inducible nitric oxide synthase and pharmacologic antagonism of platelet-activating factor.

  1999cites this paper
• Immune dysfunction in trauma.

  1999cites this paper
• Molecular Basis of the Interaction between Plasma Platelet-activating Factor Acetylhydrolase and Low Density Lipoprotein*

  1999cites this paper
• The platelet-activating factor antagonist BB-882 does not improve tissue oxygen extraction in endotoxic shock.

  1998cites this paper
• Mediators in polytrauma – pathophysiological significance and clinical relevance

  1998cites this paper
• An update on endotoxaemia Part 1: mechanisms and pathways

  1998cites this paper
• Regulation and Genetic Determination of Inflammatory Processes and Their Diagnostic Relevance

  1998cites this paper
• Low molecular weight heparin alters porcine neutrophil responses to platelet-activating factor.

  1998cites this paper